Krystal Biotech (KRYS) shares moved after the company reported first quarter 2026 results, with earnings per share above estimates and revenue growth tied to strong Vyjuvek uptake, and reaffirmed expense guidance.

The stock has built solid momentum over the past year, with a 1-year total shareholder return of 128.6% and a year to date share price return of 22.24%. The latest 1-day move of 2.94% after earnings suggests investors are reassessing growth potential and risk around Vyjuvek and the wider pipeline.

If this kind of biotech move has your attention, it can be useful to see what else is out there through a focused screen of healthcare and AI opportunities such as 39 healthcare AI stocks

With Krystal Biotech now trading at US$301.82, an intrinsic value estimate that sits at a large discount and analyst targets only slightly higher, the key question is simple: is there still a mispricing here, or is the market already baking in the next leg of growth?

Most Popular Narrative: 6.5% Undervalued

Krystal Biotech's most followed narrative sets a fair value of $322.78 against a last close of $301.82, framing the current debate around future execution.

The expansion of Krystal's pipeline, including imminent and near-term clinical readouts in lung disease (AATD, CF), ophthalmology, oncology (NSCLC), and aesthetics, leverages increased R&D productivity, which could drive future revenue growth and diversify earnings beyond a single product.

Want to see what kind of earnings curve, revenue build, and margin profile this narrative is leaning on? The projected mix between Vyjuvek cash flows and pipeline contributions may surprise you.

Result: Fair Value of $322.78 (UNDERVALUED)

However, the story can change quickly if Vyjuvek volumes become more volatile than expected, or if reimbursement timelines in new markets slip and weigh on earnings visibility.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: High Multiple, Higher Expectations

While the SWS DCF model points to Krystal Biotech trading at a 62.6% discount to its estimated future cash flow value of $807.74, the current P/E of 39.5x tells a different story. That multiple sits well above the fair ratio of 33.2x, the US Biotechs industry at 16.4x, and a peer average of 8.5x. This suggests the market is already paying a premium and leaving less room if growth or margins come in below assumptions. Which side of that gap do you think matters more?

Next Steps

Feeling torn between the upbeat valuation work and the premium multiples on show? Act while the details are fresh, review the data yourself, and weigh up the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop your research here, you could miss stocks that better fit your goals, so keep pushing your edge with tools built to surface clear opportunities.

• Target resilient income streams by scanning companies that qualify as 10 dividend fortresses
• Hunt for quality at a discount by checking out screener containing 22 high quality undiscovered gems that the market may not be watching closely yet.
• Prioritise balance sheet strength by focusing on companies featured in the solid balance sheet and fundamentals stocks screener (47 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.